-Firstpost.com It is becoming increasingly difficult to retain respect for Nobel laureate Amartya Sen. He seems to surface in the media every time the UPA government is about to legislate its pet follies, providing intellectual succour to mindless spending and corruption wrapped up in the package of anti-poverty schemes. Yesterday, Sen bobbed up just when the UPA - under siege for every known scam in India - tried to start discussions on...
More »SEARCH RESULT
Total Matching Records found : 300
In the ‘pharmacy of the world’ -PT Jyothi Datta
-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...
More »The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri
-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...
More »Landmark verdict -V Venkatesan
-Frontline The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...
More »Superior packaging can’t be used to raise prices: High Court to Sanofi SA -Maulik Vyas
-The Economic Times MUMBAI: In a setback to Sanofi SA, the Bombay High Court has dismissed the plea filed by the French pharmaceutical major saying 'superior' packaging cannot be the argument for higher pricing of drugs. The court order also clarified that fixing the prices of drugs in the country will remain in the domain of the National Pharmaceutical Pricing Authority. In its argument, the pharmaceutical company had said it had relied...
More »
